MOTS-c Pharmacokinetics (ADME): Absorption, Distribution, Metabolism, and Elimination

HealthRX.com

No human pharmacokinetic data exist for MOTS-c

912 to 970 daysMedian lifespan in mice given a late-life MOTS-c scheduleSource: fda.gov

Print or save as PDF

Key numbers

  • 5 mgProposed injection strength nominated to FDA, not a dose tested in peopleSource: fda.gov, as cited Nov 8, 2026
  • 0.5 to 15 mg/kgMouse dose range in animal studies, which FDA says cannot be converted to a human doseSource: fda.gov, as cited Nov 8, 2026
  • 20%Lower body weight in mice on a high-fat diet after 8 weeks of injected MOTS-cSource: fda.gov, as cited Nov 8, 2026
  • 912 to 970 daysMedian lifespan in mice given a late-life MOTS-c scheduleSource: fda.gov, as cited Nov 8, 2026

See the public record for MOTS-c

  • Human pharmacokinetics / none found in the FDA review [1]
  • Animal pharmacokinetics / none in living animals [1]
  • Only kinetic finding / rapid breakdown in human blood in vitro [1]
  • Approved dose / none [1]
  • Proposed doses / 5 mg and 10 mg subcutaneous injections [1]
  • Peptide size / 16 amino acids, about 2174.6 g/mol [1]
  • FDA status / not an approved drug [1]
  • Sport / prohibited at all times by WADA [2]

What is the only kinetic finding?

The one kinetic observation FDA cites is an in-vitro experiment in which MOTS-c was quickly broken down in human blood; the agency noted that this raises the question of whether injecting the peptide can produce active levels in people [1]. It is a laboratory result about peptide stability in blood, not a measurement of peptide levels after an injection.

The molecule is a 16-amino-acid peptide (Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg) of about 2174.6 g/mol, encoded in mitochondrial DNA and first reported in 2015 by Lee and colleagues in Cell Metabolism [1][3].

Can a Tmax, Cmax or half-life be quoted?

No measured Tmax, Cmax, half-life, bioavailability or volume of distribution has been reported. The products nominated to FDA were 5 mg and 10 mg subcutaneous injections; these were proposed strengths, not doses tested in people [1]. Mouse experiments used 0.5 to 15 mg/kg, and FDA states those doses cannot be converted into human doses [1].

Questions worth asking

Choose the questions you want to keep

What did the animal work actually measure?

In mice, injected MOTS-c reduced weight gain on a high-fat diet, with about 20% lower body weight after 8 weeks at 0.5 mg/kg/day intraperitoneal [1]. A late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [1]. Lee and colleagues reported that treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the apparent main target organ and AMPK activation [3]. FDA notes that the molecular targets are unknown and that dose-response relationships were not assessed [1].

Does exercise raising your own MOTS-c say anything about injections?

In a randomized trial of 30 healthy adults assigned to endurance exercise (n=10, 45 minutes of cycling at 70% of estimated VO2max), resistance exercise (n=10) or control (n=10), humanin rose significantly after endurance exercise, MOTS-c showed only a trend to increase, and plasma MOTS-c was not related to fitness [5]. Exercise has also been shown to induce endogenous MOTS-c expression in human skeletal muscle and in the circulation, in people who were not given MOTS-c [4]. Both studies measured the body's own peptide.

What do regulators say about the injected product?

MOTS-c is not an FDA-approved drug and is not a component of one, and FDA found no pharmacopoeial monograph for it and no product authorised by the European Medicines Agency [1]. For injectable peptides the agency's stated concern is immunogenicity from aggregation and peptide-related impurities, and no immunogenicity data exist for MOTS-c [1][6]. FDA's adverse-event database searches through March 9, 2025 retrieved no MOTS-c reports, and the agency found no animal toxicity studies [1]. WADA names MOTS-c in S4.4.1 among AMPK activators, prohibited at all times in and out of competition [2]. An HHS draft policy from October 2026 on certain compounded peptides names MOTS-c acetate for injection; the notice states it is not binding, and it is not an approval or a listing [7][8].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What kind of result is the only kinetic finding for MOTS-c in the article?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Does the human blood experiment predict what an injection does?
It does not. The experiment showed that MOTS-c is quickly broken down when mixed with human blood in the laboratory, and it was not a measurement of peptide levels after an injection in a person [1].
What doses of MOTS-c have been proposed for people?
The uses nominated to FDA were 5 mg and 10 mg subcutaneous injections, for insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity [1]. Those were proposed strengths, not doses tested in people, and no approved dose exists [1].
Do the mouse doses convert to a human dose?
No conversion is established. Mouse studies used 0.5 to 15 mg/kg, and FDA states those doses cannot be converted into human doses [1].
Does exercise raising my own MOTS-c mean an injection behaves the same way?
They are different measurements. In a randomized trial of 30 healthy adults, endurance exercise produced only a trend toward higher circulating MOTS-c, and plasma MOTS-c was not related to fitness; nobody received MOTS-c [5].
Is MOTS-c approved anywhere?
MOTS-c is not an FDA-approved drug or a component of one, and no product containing it is authorized by the European Medicines Agency [1]. FDA staff recommended against adding it to the compounding bulks list, and the July 2026 advisory committee vote in its favor was advice only and not binding [1][9].
Is MOTS-c banned in sport?
Yes. WADA names MOTS-c in S4.4.1 among AMPK activators, prohibited at all times in and out of competition, and it appears on the 2026 List and on the 2027 List [2][10].
Show all 10 referencesHide references
  1. U.S. Food and Drug Administration.
  2. World Anti-Doping Agency.
  3. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  4. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
  5. von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
  6. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  7. Official web page.
  8. Official web page.
  9. U.S. Food and Drug Administration.
  10. World Anti-Doping Agency.
Evidence overview for MOTS-c Pharmacokinetics (ADME): Absorption, Distribution, Metabolism, and Elimination